Vladan Vučinić

Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia

Wolfgang Bethge, Jolanta Dengler, M Bornhäuser et al. · Leukemia · 2012 · 230 citations

Medicine, Hematology, Oncology +14

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

Wolfgang Bethge, Peter Martus, Michael Schmitt et al. · Blood · 2022 · 211 citations · Full text

Medicine, Hematology, Oncology +15

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis

Daniel Fürst, Carlheinz Müller, Vladan Vučinić et al. · Blood · 2013 · 209 citations

Medicine, Hematology, Immunology +15

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Peter Borchmann, Justin Ferdinandus, Gundolf Schneider et al. · The Lancet · 2024 · 114 citations · Full text

Medicine, Oncology, Pharmacology +15

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Nico Gagelmann, Danai Dima, Maximilian Merz et al. · Journal of Clinical Oncology · 2024 · 83 citations · Full text

Medicine, Immunology, Oncology +17